Purdue to pay $16 million for suppressing generic brands of OxyContin

Purdue Pharma, manufacturer of prescription pain pill OxyContin, will pay $16 million to direct purchasers of the drug who claim Purdue obtained patents through misleading information, according to this article in the Wall Street Journal. Since the patents were filed in the 1990s, purchasers of the drug accused the pharmaceutical company of using invalid patents to sue companies making generic versions of OxyContin, thereby delaying the FDA approval process for those generics, reports Law 360. Purdue has already settled the majority of 57 similar cases.

Read about other cases against Purdue from makers of generic OxyContin here.

About Dana Owens

Dana Owens is San Francisco-based writer, editor and blogger who works on diverse projects from holistic health research to record label promotion. In addition to lending her editorial eye to Oxy Watchdog, Dana also acts as copyeditor for 99 Series, Inc. and executive assistant/project coordinator for Heartline Productions.
This entry was posted in Litigation, Pharmaceutical Industry and tagged , , , . Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *